Laureate Institute for Brain Research, Inc.
lbr.orgTotal trials
53
Active
14
Phase 3
2
Total enrollment
5,529
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Lorazepam | — | — | — | — | — | 1 | |
| Ibuprofen 800 mg | — | — | — | — | — | 1 | |
| LPS | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 |
Next readouts
- 2026-04
- 2026-12-31
- 2027-12-31
Top conditions
- Depression11
- Major Depressive Disorder9
- Anxiety7
- Anorexia Nervosa6
- Generalized Anxiety Disorder5
- Panic Disorder4
- Social Anxiety Disorder3
- Agoraphobia3
Frequently asked questions about Laureate Institute for Brain Research, Inc.
- How many clinical trials does Laureate Institute for Brain Research, Inc. have on ClinicalTrials.gov?
- Laureate Institute for Brain Research, Inc. is listed as the lead sponsor on 53 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Laureate Institute for Brain Research, Inc.'s trials are in Phase 3?
- 2 of Laureate Institute for Brain Research, Inc.'s trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Laureate Institute for Brain Research, Inc. focus on?
- Laureate Institute for Brain Research, Inc.'s most-studied conditions on ClinicalTrials.gov are Depression, Major Depressive Disorder, Anxiety, Anorexia Nervosa, Generalized Anxiety Disorder.
- When are Laureate Institute for Brain Research, Inc.'s next clinical trial readouts?
- Laureate Institute for Brain Research, Inc. has 3 upcoming primary-completion readouts tracked here; the soonest is “Neural Response to Inflammatory Challenge in Major Depressive Disorder”, expected around 2026-04.